Mohammad AskarPublic working copy · medical review pending

Medical glaucoma strategies · 215

Glaucoma medication: target pressure, safety and adherence

Choose a pressure-lowering treatment that the patient can use safely, then judge its effect against structural and functional follow-up.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

An individual target pressure guides treatment; tolerability, instillation technique and measured progression determine whether the plan works. Pressure lowering reduces risk but cannot guarantee preservation of vision.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Start with the optic nerve and the patient’s goal

Glaucoma is an optic neuropathy with characteristic structural and functional damage. Intraocular pressure (IOP) is an important modifiable risk factor, but neither a single pressure reading nor a normal-range value defines the whole disease. 1

Mechanical stress and vascular vulnerability are explanatory models; they do not yield a guaranteed protective pressure for every eye. 1

The lecture traces treatment from pilocarpine through timolol, dorzolamide and latanoprost to Rho-kinase (ROCK) inhibitors and nitric-oxide-donating latanoprost bunod. EGS describes glaucoma drugs as available since 1875. 1 10

Pilocarpine retains selected open-angle and angle-closure uses, with mechanism-specific assessment; the remaining historical dates in the original lecture are not verified milestones in this draft. 1 10

UKGTS was a masked, placebo-controlled randomised trial in 516 people with newly diagnosed open-angle glaucoma. At 24 months, latanoprost prolonged time to visual-field deterioration: adjusted HR 0.44 (95% CI 0.28–0.69; p=0.0003). 2

Early stopping and a change to the primary outcome after interim analysis require attention. This supports visual-field protection in that population, not guaranteed lifelong protection or a class-wide effect for every drug. 2

02Set the target and interpret the measurements

Set a target for each eye using untreated pressure, damage, progression rate, life expectancy, fellow-eye status and treatment burden. EGS gives examples of 18–20 mmHg with ≥20% reduction in early disease, 15–17 mmHg with ≥30% reduction in moderate disease, and 8–12 mmHg in advanced disease. 1

These are starting estimates, not mandatory stage thresholds; evidence for any particular algorithm is limited. 1

Document pressure, gonioscopy, optic nerve/retinal nerve fibre layer (RNFL) assessment, optical coherence tomography (OCT) and visual fields. Goldmann applanation is a reference method; non-contact readings alone cannot establish longitudinal control. 1

Central corneal thickness helps interpret tonometry, but EGS advises against numerical IOP correction with thickness-based formulas. Confirm suspected OCT or field change before declaring progression. 1

In normal-tension glaucoma (NTG), ask about migraine, Raynaud phenomena and systemic hypotension without treating them as proven causes of progression in an individual. Daytime readings can miss pressure peaks; use a diurnal or circadian profile when it answers a clinical question. 1 4 5

Short-term drug studies show different day/night responses, including weaker nocturnal timolol effects, but do not prove that suppressing every fluctuation preserves vision. 1 4 5

A prospective cohort of 85 NTG patients associated longer periods of sleep-time mean arterial pressure more than 10 mmHg below daytime levels with subsequent field progression over 12 months. 4

This is observational evidence, not a trial of changing antihypertensive timing. Suspected nocturnal hypotension warrants coordinated assessment; patients should not stop or reschedule cardiovascular treatment themselves. 4

03Choose the class and anticipate adverse effects

Drug classes reduce aqueous production, enhance uveoscleral outflow or improve conventional trabecular drainage. The table keeps the lecture’s five classes. 1

Approximate EGS pressure reductions describe populations, not a prescription or a head-to-head ranking. The lecture’s production/outflow percentages cannot be substituted for pressure effects. 1

Prostaglandin analogues (PGA) are often an initial medication because they are effective and usually once daily. Discuss hyperaemia, iris/skin pigmentation, lash growth and periorbital changes. 1 6

Prior herpetic keratitis, uveitis and cystoid macular oedema (CME) risk require product-specific assessment; once-daily use may simplify treatment but does not guarantee adherence or constant pressure throughout the day. 1 6

Topical beta-blockers such as timolol can cause bronchospasm, bradycardia, atrioventricular block and hypotension. Check asthma, relevant pulmonary disease, pulse, cardiac history and all systemic beta-blocker treatment. 1

Systemic absorption and overlapping blockade matter; the lecture’s receptor-saturation explanation is not an established rule for predicting response. A beta-1-selective preparation is not free of respiratory or cardiac risk. 1

Topical carbonic anhydrase inhibitors (CAI), dorzolamide and brinzolamide, differ from systemic acetazolamide. Review corneal endothelial status for topical treatment and renal/hepatic function, electrolytes and acidosis risk for systemic treatment. 1

Potassium loss and kidney stones are relevant systemic harms. Neither a topical class label nor a favourable pressure response makes systemic use safe in a vulnerable patient. 1

Choose the class and anticipate adverse effects
Drug classMechanism and approximate IOP reductionClinical use and limitations
PGA: latanoprostUveoscleral outflow increased; 25–35%Often initial medication, usually once daily; pigmentation, hyperaemia, periorbital effects; inflammation/CME risk assessed individually
Beta-blockers: timololAqueous production reduced; 20–25% for non-selective agentsCheck respiratory/cardiac contraindications and systemic beta-blockers; nocturnal effect may be weaker
Alpha-2 agonists: brimonidineProduction reduced and uveoscleral outflow increased; 18–25%Allergy, fatigue, somnolence; no established routine neuroprotection; product-specific child/apnoea restrictions
CAI: dorzolamide, brinzolamide; systemic acetazolamideProduction reduced; topical about 20%; systemic acetazolamide 30–40%Topical endothelial caution; systemic renal, electrolyte, acidosis and stone risks; no universal uveitis-first-choice claim
ROCK inhibitors: netarsudil, ripasudilTrabecular outflow increased; netarsudil 20–25%, ripasudil 20%Hyperaemia and cornea verticillata; local authorisation and availability differ; no universal PGA comparison

04Brimonidine, children and newer mechanisms

LoGTS randomised low-pressure glaucoma patients to brimonidine (99) or timolol (79), with mean follow-up 30±2 months. Field progression was reported in 9/99 (9.1%) versus 31/79 (39.2%) despite similar treated IOP. Drug-related adverse-effect withdrawal was 28/99 (28.3%) versus 9/79 (11.4%). 3

Differential withdrawal and the selected population prevent a confident general claim of pressure-independent neuroprotection. 3

Brimonidine may cause allergy, dry mouth, fatigue and somnolence; apraclonidine has a distinct short-term clinical role and sensitisation profile. A single universal allergy percentage is not established here. 1 3

EGS does not support routine neuroprotective agents as established glaucoma treatment. The LoGTS erratum and complete report still need inspection before final appraisal. 1 3

For German Alphagan 0.2%, the March 2026 product information distinguishes contraindication below 2 years from use not recommended below 12 years. Children aged 2–7 years and/or weighing ≤20 kg need particular caution and monitoring for somnolence if treated by a specialist. 7

These are different categories, not permission to prescribe routinely from age 2. Do not transfer adult regimens or an unverified childhood efficacy percentage; full paediatric management remains in childhood glaucoma lecture. 7

ROCK inhibition improves trabecular outflow; netarsudil also lowers episcleral venous pressure. Discuss hyperaemia and vortex keratopathy (cornea verticillata), without assuming a universal adverse-effect ranking against PGA. 1 8 9

Rhokiinsa (netarsudil) has an EU regulatory record; latanoprost bunod has a separate US product record. Neither proves current German supply, reimbursement or interchangeability. Pilocarpine remains a separate miotic, not a ROCK inhibitor. 1 8 9

05Make the regimen usable and protect the ocular surface

Polypharmacy can increase ocular surface disease (OSD), daily burden and difficulty maintaining treatment. Benzalkonium chloride (BAC) may cause or worsen surface symptoms, but not every patient is sensitive and not every symptom is preservative-related. 1 6

Consider preservative-free or BAC-free products, suitable fixed combinations and treatment of surface disease. A universal discontinuation rate attributable to hyperaemia is not established. 1 6

Adherence concerns how treatment is used; persistence concerns how long it is continued. Ask without blame about missed doses, cost, bottle handling, help from others and side effects. 1

A demonstration often reveals problems that a yes/no question misses. More drops do not automatically mean better real-world control; simplify the schedule and agree on a feasible plan. 1

Separate drops to reduce washout and follow the specific product instructions. EGS gives a general minimum of 2 minutes; German Xalatan information requires at least 5 minutes between different topical ophthalmic products. 1 6

The lecture’s universal 5–10-minute rule should not replace the label. 1 6

Eyelid closure and punctal occlusion reduce systemic exposure; Xalatan specifies 1 minute of punctal compression. Do not touch the eye with the bottle tip. 1 6

06Plan pregnancy and breast-feeding individually

Discuss pregnancy plans before conception where possible. A fall in IOP during pregnancy does not ensure stability; maternal visual risk must be balanced against fetal and neonatal drug exposure. 1 6

Temporary withdrawal may be reasonable in selected patients under strict follow-up, but no fixed pressure threshold or months-long waiting rule establishes safety. Do not stop treatment without a coordinated plan. 1 6

No glaucoma drop has a universal pregnancy-safety guarantee. Human evidence is limited, and animal reproductive findings do not quantify human risk. 1 6 7

The German Xalatan label advises against pregnancy use; EGS discussion of possible PGA use during breast-feeding is broader than that product label, which advises avoidance or stopping breast-feeding. 1 6 7

Keep this discrepancy visible and choose using the current local product information with obstetric and paediatric input. 1 6 7

Brimonidine must be avoided in late pregnancy and during breast-feeding because of infant central nervous system depression and apnoea risk; “postpartum” alone does not mean “breast-feeding”. 1 7

CAI, beta-blockers and pilocarpine require their own contraindication and timing assessment. Reduce systemic absorption if drops are necessary. 1 7

Laser may be discussed where the angle and clinical circumstances are suitable, but SLT is not established as the universally safest pregnancy treatment. 1 7

07Uveitis and inadequate control: reassess before escalating

Uveitic pressure elevation can reflect trabeculitis, inflammatory obstruction, synechiae or a steroid response. Control the inflammation as well as pressure. 1 6

EGS describes topical beta-blockers and CAI as traditional first-line options; this does not make CAI the universal first choice. 1 6

PGA may be considered in well-controlled uveitis, with caution for inflammation and CME risk, especially in aphakic or vulnerable pseudophakic eyes. Neither blanket prohibition nor guaranteed safety in every quiet eye is justified. 1 6

Start with a suitable single medication when appropriate; very high pressure or severe disease may justify an initial combination. 1

If the first drug is ineffective or poorly tolerated, consider switching. 1

If it works but is insufficient, add a complementary mechanism, often using a suitable fixed combination to reduce bottles and preservative exposure. Check duplication, interactions and actual use before each change. 1

If confirmed progression threatens meaningful vision despite treatment, reconsider the target, adherence and diagnosis and discuss laser or surgery without waiting for every possible drop to fail. 1 11

EGS guidance, individual trials and German DOG/BVA documents have different scopes. The unidentified “S3 legal standard” in the lecture is not a verified treatment guideline or proof of a binding legal rule. 1 11

08Keep surgical choices and clinical pearls in context

Trabeculectomy remains an important option when a low target pressure is needed. The lecture’s goal below 10 mmHg needs individual assessment; it is not a guaranteed effect or proof of superiority for every patient. 1

Conjunctival scarring affects bleb surgery feasibility and prognosis; it is not a universal absolute contraindication. Balance hypotony, scarring, postoperative care and the risk of ongoing disease. 1

Conventional-outflow minimally invasive glaucoma surgery (MIGS), subconjunctival microshunts and long-tube drainage devices are distinct groups. PreserFlo is a bleb-forming subconjunctival procedure; it should not inherit every claim about trabecular MIGS. 1

The lecture’s universal greater “predictability” and frequency of pressures below 10 mmHg are not established here. Advanced scarring can limit bleb procedures while prompting consideration of other drainage strategies. 1

Deep sclerectomy is a non-penetrating option for selected open-angle eyes. EGS describes fewer hypotony-related complications but less long-term pressure lowering than trabeculectomy; surgical learning and possible additional procedures also matter. 1

Angle closure and iris neovascularisation require mechanism-specific reassessment, not automatic transfer of open-angle indications. Full surgical decisions belong in the dedicated surgery review. 1

The lecture’s clinical pearls, including its reference to Syrian clinical experience and resource-limited settings, are teaching perspectives rather than comparative evidence. 1 10

Apply them by asking what the patient can obtain, tolerate and use, then verify the result over time. 1 10

The six-row review table preserves the original themes; neither it nor voluntary recall replaces the full lecture or clinical judgement. 1 10

Keep surgical choices and clinical pearls in context
TopicOriginal clinical focusWhat to checkEvidence boundaryRisks and exceptions
Beta-blockersSystemic treatment can alter the topical responseAsthma, pulse, AV block, concurrent drugsDay/night pressure effects differ; no universal receptor-saturation ruleBronchospasm, bradycardia, hypotension
BrimonidinePressure lowering; proposed neuroprotectionLocal allergy, CNS effects, age/product restrictionsLoGTS does not establish routine neuroprotectionInfant apnoea; late pregnancy/breast-feeding avoidance
PregnancyObservation, medication or suitable laserStage, progression, gestation, label, maternal/fetal risksNo universal pressure/waiting rule or safest-treatment rankingPGA reproductive caution; brimonidine late pregnancy/breast-feeding
TrabeculectomyLow target pressure or progression despite treatmentConjunctiva, scarring risk, capacity for postoperative careLecture goal <10 mmHg requires individual assessment; no guaranteed effectHypotony, bleb complications; scarred conjunctiva affects planning
MIGS / microshunts / tubesAlternatives selected for mechanism and targetDistinguish trabecular procedures from PreserFlo and long tubesNo universal predictability ranking or frequency of <10 mmHgScarring limits bleb procedures; procedure-specific hypotony/failure risks
Deep sclerectomyNon-penetrating approach in selected open-angle diseaseAngle anatomy, iris neovascularisation, surgeon experienceFewer hypotony complications but less long-term lowering than trabeculectomyAngle closure/rubeosis require reassessment; further intervention may be needed
What are the main learning points?

An individual target pressure guides treatment; tolerability, instillation technique and measured progression determine whether the plan works. Pressure lowering reduces risk but cannot guarantee preservation of vision.

When is assessment urgent?

Seek immediate help for breathlessness, fainting or a severe allergic reaction. A single missed drop is usually not an emergency; ask your team or pharmacist if uncertain about the next dose.

References and access status

  1. 1
    EGS Terminology and Guidelines for Glaucoma, 6th edition (2025)

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Supplied local PDF text inspected: target IOP pp163–169, drug tables/OSD pp170–180, pregnancy section p181, neuroprotection/technique/adherence pp184–186; CCT section p80; uveitis pp132–133; selected surgical sections pp193–195 and 201. Extracted tables, not a new visual table appraisal or whole-book reading. DOI 10.1136/bjophthalmol-2025-egsguidelines.

  2. 2
    Garway-Heath et al. UKGTS (2015), DOI 10.1016/S0140-6736(14)62111-5

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Indexed primary abstract inspected; direct PubMed retrieval incomplete. Complete paper/protocol/supplement unread. Masked RCT, early stopping and changed outcome retained.

  3. 3
    Krupin et al. LoGTS (2011), DOI 10.1016/j.ajo.2010.09.026

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Complete primary abstract directly read. Main article/supplements and linked erratum unread; selected population and differential adverse-effect withdrawal retained. Not proof of general neuroprotection.

  4. 4
    Charlson et al. Nocturnal systemic hypotension and progression (2014)

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Primary indexed abstract inspected; full report unread. Prospective observational association, not a trial of changing antihypertensive treatment.

  5. 5
    Orzalesi et al. Circadian IOP effects of timolol, latanoprost and dorzolamide (2000)

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Indexed primary abstract passages inspected; complete report unread. Short-term circadian pressure findings are not long-term visual outcomes.

  6. 6
    Xalatan 50 micrograms/ml, German Fachinformation, July 2025

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Official product-information sections 4.1–4.6 inspected in indexed/direct HTML, including spacing, punctal compression, uveitis/CME caution and pregnancy/lactation. Not a full PDF/table appraisal or a class-wide instruction.

  7. 7
    Alphagan 0.2%, German Fachinformation, March 2026

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Access carried forward from review 007 followup-device-drug.md: sections 4.1–4.4 and paediatric 4.8, PDF pp1 and 4 visually checked in that review. Not a new full-label reading; no adult-to-child regimen transfer.

  8. 8
    EMA: Rhokiinsa (netarsudil)

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Official indexed regulatory overview inspected; direct retrieval rate-limited. No German supply/reimbursement claim and no newly inspected full SmPC.

  9. 9
    DailyMed: Vyzulta (latanoprost bunod), US label record

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Official indexed record inspected, updated 27 February 2024; full label not read. US record is not evidence of German authorisation.

  10. 10
    Immutable original export; own medical glaucoma lecture; historical dates and examiner attribution unchecked

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  11. 11
    DOG/BVA AWMF 045-015 S2e, risk factors for open-angle glaucoma (2024)

    Historical 009-glaucoma-medication appraisal reused; not new full-source access. Official title/grade/scope carried forward from review 008 source check, not a new full reading. This risk-factor guideline does not substantiate the unspecified S3 legal/treatment attribution.

Original lecture link